KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Chemistry / 2018 / Cilt: 42 - Sayı: 3

Schiff base of isoniazid and ketoprofen: synthesis, X-ray crystallographic, spectroscopic, antioxidant, and computational studies

Muhammad Nawaz TAHIR
Uzma YUNUS
Faiz AHMED
Moazzam Hussain BHATTI
Muhammad KHALID
Naima REHMAN
Ataualpa Albert Carmo BRAGA
Syed Muddassir ALI MASHHADI
Sayfa
639–651
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Different experimental (XRD, IR, thermal gravimetricanalysis, differential scanning calorimetry) and computational studies correlate and validate findings related to this novelSchiff base.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Ketoprofen and isoniazid together are a potential combination of a nonsteroidal antiinflammatory drugand an antitubercular medicine to treat tuberculosis and associated symptoms like fever and fatigue.
📊
Temel Bulgular & Veri:The complete geometrical optimization of the monomer andhydrogen-bonded dimer of the Schiff base is performed utilizing M06-2X/6-31G(d,p) level theory and compared withthe experimental data to optimize the molecular structure.
💡
Sonuç & Katkı:Different experimental (XRD, IR, thermal gravimetricanalysis, differential scanning calorimetry) and computational studies correlate and validate findings related to this novelSchiff base.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Ketoprofen and isoniazid together are a potential combination of a nonsteroidal antiinflammatory drugand an antitubercular medicine to treat tuberculosis and associated symptoms like fever and fatigue. The Schiff baseof isoniazid with ketoprofen is synthesized in this research. Infrared spectroscopy (IR) and X-ray diffraction (XRD)analysis of the crystal packing proved the formation of the Schiff base and the existence of N-H· · ·O hydrogen bondsbetween the hydrogen-bonded dimer of the Schiff base. The complete geometrical optimization of the monomer andhydrogen-bonded dimer of the Schiff base is performed utilizing M06-2X/6-31G(d,p) level theory and compared withthe experimental data to optimize the molecular structure. The effect of 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicalscavenging activity shows that the synthesized Schiff base has improved antioxidant activity. Molecular docking studiesagainst Mycobacterium tuberculosis (Mtb) RNA polymerase-related targets with PDB codes 2M6O and 4KBJ and lungsurfactant protein A (SP-A) with PDB ID 5FFT suggest that it can be screened as a potent drug against Mtb infectionof the lungs. Frontier orbital theory analysis shows a high energy gap between the HOMO and LUMO, which suggeststhat the reported Schiff base might be a bioactive compound. Different experimental (XRD, IR, thermal gravimetricanalysis, differential scanning calorimetry) and computational studies correlate and validate findings related to this novelSchiff base.

🔖

Bu Makaleye Atıf Yap

TAHIR, M. N., YUNUS, U., AHMED, F., BHATTI, M. H., KHALID, M., REHMAN, N., BRAGA, A. A. C., MASHHADI, S. M. A. (2022). Schiff base of isoniazid and ketoprofen: synthesis, X-ray crystallographic, spectroscopic, antioxidant, and computational studies. Turkish Journal of Chemistry, Cilt: 42 - Sayı: 3, 639–651. https://ajindex.com/articles/601962

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (29)

  1. Kwiatkowska, S.; Piasecka, G.; Zieba, M.; Piotrowski, W.; Nowak, D. Respir. Med. 1999, 93, 272-276
  2. Walubo, A.; Smith, P. J.; Folb, P. I. Biomed. Environ. Sci. 1995, 8, 106-113
  3. Strausz, J.; Muller-Quernheim, J.; Steppling, H.; Nagel, M.; Ferlinz, R. Pub. Med. 1990, 44, 222-223
  4. Charles, M. H.; Simon, J. G.; John, H. Int. J. Pharm. 2003, 261,165-169
  5. Yalcin, T.; Gulgun, Y.; Umit, G. Farmaco 1999, 54, 648-652
  6. Jachowicz, R.; Nurnberg, E.; Pieszczek, B. Int. J. Pharm. 2000, 206, 13-21
  7. Lagrange, F.; P´enhourcq, F.; Matoga, M.; Bannwarth, B. J. Pharm. Biomed. Anal. 2000, 23, 793-802
  8. Tettey-Amlalo, R. N. O.; Kanfer, I. J. Pharm. Biomed. Anal. 2009, 50, 580-586
  9. Vergote, G. J.; Vervaet, C.; Driessche, I. V. Int. J. Pharm. 2001, 219, 81-87
  10. Makiko, F.; Naohide, H.; Kumi, S. Int. J. Pharm. 2000, 20, 117-125
  11. Schultheiss, N.; Newman, A. Cryst. Growth Des. 2009, 9, 2950-2967
  12. Jones, W. D. S.; Motherwell, A. V. MRS Bull. 2006, 31, 875-879
  13. Almarsson, O.; Zaworotko, M. J. Chem. Commun. 2004, 17, 1889-1896
  14. Mashhadi, S. M. A.; Yunus, U.; Bhatti, M. H.; Tahir, M. N. J. Mol. Struc. 2014, 1076, 446-452
  15. Mashhadi, S. M. A.; Yunus, U.; Bhatti, M. H.; Ahmad, I.; Tahir, M. N. J. Mol. Struc. 2016, 1117, 17-21
  16. Sathe, B. S.; Jaychandran, E.; Jagtap, V. A.; Sreenivasa, Int. J. Pharm. Res. Dev. 2011, 3, 164-169
  17. Sondhi, S. M.; Singh, N.; Kumar, A.; Lozach, O.; Meijer, L. Bioorg. Med. Chem. 2006, 14, 3758-3765
  18. Pandey, A.; Dewangan, D.; Verma, S.; Mishra, A.; Dubey, R. D. Int. J. Chem. Tech. Res. 2011, 3, 178-184
  19. Chinnasamy, R. P.; Sundararajan, R.; Govindaraj, S. J. Adv. Pharm. Tech. Res. 2010, 1, 342-347
  20. Wei, D.; Li, N.; Lu, G.; Yao, K. Science in China B 2006, 49, 225-229
  21. Sidwell, R. W.; Huffman, J. H.; Khare, G. P.; Allen, L. B.; Witkowski, J. T.; Robins, R. K. Science 1972, 177, 705-706
  22. Witkowski, J. T.; Robins, R. K.; Khare, G. P.; Sidwell, R. W. J. Med. Chem. 1973, 16, 935-937
  23. Clemons, M.; Coleman, R. E.; Verma, S. Cancer Treat. Rev. 2004, 30, 325-332
  24. Budavari, S. The Merck Index; Merck: Whitehouse Station, NJ, USA, 1996
  25. Haber, J. J. Czech Phys. 2001, 140, 596-604
  26. Walczak, K.; Gondela, A.; Suwi´nski, J. Eur. J. Med. Chem. 2004, 39, 849-853
  27. Holla, B. S.; Poojary, K. N.; Rao, B. S. Eur. J. Med. Chem. 2002, 37, 511-517
  28. Holla, B. S.; Veerendra, B.; Shivananda, M. K. Eur. J. Med. Chem. 2003, 38, 759-767
  29. Amir, M.; Shikha, K. Eur. J. Med. Chem. 2004, 39, 535-545